ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 41.69% |
2ABBV | ABBVIE INC | Healthcare | $520.47B | 16.16% |
3ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 5.77% |
4ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 4.73% |
5SYK | STRYKER CORP | Healthcare | $118.92B | 3.69% |
6REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 3.06% |
7MRNA | MODERNA INC | Healthcare | $93.61B | 2.91% |
8EW | EDWARDS LIFESCIENCES CORP | Healthcare | $60.84B | 1.89% |
9IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 1.71% |
10VEEV | VEEVA SYSTEMS INC | Healthcare | $48.96B | 1.52% |
11ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 1.47% |
12RMD | RESMED INC | Healthcare | $33.60B | 1.04% |
13ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.90% |
14WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $28.65B | 0.89% |
15STE | STERIS PLC | Healthcare | $24.61B | 0.76% |
16VTRS | VIATRIS INC | Healthcare | $23.70B | 0.74% |
17THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 0.71% |
18MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 0.57% |
19NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.53% |
20JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 0.48% |
21BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $14.22B | 0.44% |
22TEM | TEMPUS AI INC | Healthcare | $13.84B | 0.43% |
23EHC | ENCOMPASS HEALTH CORP | Healthcare | $13.82B | 0.43% |
24BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 0.41% |
25ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 0.41% |
26PEN | PENUMBRA INC | Healthcare | $12.64B | 0.39% |
27HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.36% |
28TECH | BIO-TECHNE CORP | Healthcare | $11.44B | 0.36% |
29PODD | INSULET CORP | Healthcare | $10.36B | 0.32% |
30BIO | BIO-RAD LABORATORIES INC | Healthcare | $9.96B | 0.31% |
31OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.31% |
32TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.30% |
33GMED | GLOBUS MEDICAL INC | Healthcare | $9.58B | 0.30% |
34KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 0.28% |
35PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 0.27% |
36HQY | HEALTHEQUITY INC | Healthcare | $8.52B | 0.26% |
37KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.23% |
38BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.23% |
39DOCS | DOXIMITY INC | Healthcare | $5.92B | 0.18% |
40LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $5.38B | 0.17% |
41PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.16% |
42MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $5.19B | 0.16% |
43EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.16% |
44SHC | SOTERA HEALTH CO | Healthcare | $4.66B | 0.14% |
45ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.12% |
46TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.12% |
47OGN | ORGANON & CO | Healthcare | $3.65B | 0.11% |
48GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $3.13B | 0.10% |
49BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.10% |
50PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.02B | 0.09% |
51ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.09% |
52ADUS | ADDUS HOMECARE CORP | Healthcare | $2.31B | 0.07% |
53SEPN | SEPTERNA INC | Healthcare | $1.99B | 0.06% |
54HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.06% |
55NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.05% |
56HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.05% |
57ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.05% |
58TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.05% |
59IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.05% |
60AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.04% |
61PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.04% |
62DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.04% |
63OMER | OMEROS CORP | Healthcare | $1.30B | 0.04% |
64TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.04% |
65IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.03% |
66IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.03% |
67CSTL | CASTLE BIOSCIENCES INC | Healthcare | $1.06B | 0.03% |
68HROW | HARROW INC | Healthcare | $1.06B | 0.03% |
69AORT | ARTIVION INC | Healthcare | $947M | 0.03% |
70MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.03% |
71ALMS | ALUMIS INC | Healthcare | $793M | 0.02% |
72DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.02% |
73CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 0.02% |
74TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.02% |
75AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $571M | 0.02% |
76MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.02% |
77CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.02% |
78PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.01% |
79SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.01% |
80ELMD | ELECTROMED INC | Healthcare | $204M | 0.01% |
81CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.00% |
82RLYB | RALLYBIO CORP | Healthcare | $84M | 0.00% |
83GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $3.22T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 89% toward Growth. +3% unclassified (11 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 83 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 83 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 28.1% | -1.0% |
| 3 yearsp.a. | 23.6% | 9.6% |
| 5 yearsp.a. | 10.7% | 1.4% |
| 10 yearsp.a. | 13.4% | 1.6% |
| Since inceptionp.a. | 10.6% | -0.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 29.4% | -0.8% |
| 2025 | 27.1% | 19.0% |
| 2024 | 8.8% | 11.9% |
| 2023 | 6.2% | 13.2% |
| 2022 | -15.0% | -22.9% |
| 2021 | 21.3% | -4.6% |
| 2020 | 14.5% | 5.1% |
| 2019 | 14.9% | -4.1% |
| 2018 | 7.1% | 2.5% |
| 2017 | 24.0% | 0.4% |
| 2016 | -7.9% | -6.9% |
| 2015 | 5.7% | -4.5% |
| 2014 | 29.4% | 1.7% |
| 2013 | 42.9% | -0.9% |
| 2012 | 18.6% | 1.6% |
| 2011 | 14.7% | -0.6% |
| 2010 | 1.2% | -12.4% |
| 2009 | 30.2% | 2.4% |
| 2008 | -13.3% | -4.5% |
| 2007 | 4.2% | -2.9% |
| 2006 | -4.3% | -14.1% |
| 2005 | 12.0% | 2.8% |
| 2004 | 12.4% | 15.5% |
| 2003 | 28.8% | -3.9% |
| 2002 | -27.0% | -7.6% |
| 2001 | -9.2% | -1.2% |
| 2000 | 44.4% | -11.1% |
| 1999 | 13.3% | 21.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare ChTax Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ChTax signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.